

# The outcome of in vitro fertilization / intracytoplasmic sperm injection in endometriosis-associated and tubal factor infertility

Ensieh Shahrokh Tehrani Nejad<sup>1,2,3</sup> M.D., Batoool Hosein Rashidi<sup>2,3</sup> M.D., Atefeh Larti<sup>3</sup> M.D., Zahra Ezabadi<sup>1</sup> M.Sc., Nadia Jahangiri<sup>1</sup> M.Sc., Elham Azimi Nekoo<sup>3</sup> M.D.

1 Department of Endocrinology and Female Infertility, Reproductive Medicine Research Centre, Royan Institute, ACECR, Tehran, Iran.

2 Department of Obstetrics and Gynecology, Tehran University of Medical Sciences, Tehran, Iran.

3 Vali-e-asr Reproductive Health Research Centre, Tehran University of Medical Sciences, Tehran, Iran.

Received: 11 September 2008; accepted: 22 February 2009

## Abstract

**Background:** Endometriosis is one of the most challenging diseases that constitute 20% - 40% of women searching for their infertility diagnosis.

**Objective:** This study was undertaken in order to compare the outcome of in vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI) in women with endometriosis, and tubal factor infertility as controls.

**Materials and Methods:** From 2005 to 2006 a retrospective study was carried out in patients with endometriosis (n=80) and tubal infertility (n=57) after treatment with IVF/ICSI. The main outcome measures were ovarian responsiveness, quality of oocytes, implantation, pregnancy and ongoing pregnancy rates. Appropriate statistical analysis was performed using  $\chi^2$  and student t-tests.

**Results:** No differences were found in mean number of ampoules of hMG, duration of hMG injection, number of MII oocytes, number of embryo transferred, and rates of implantation, pregnancy, ongoing pregnancy and twin birth between women with endometriosis and tubal infertility and also between women with stages I/II or those with stages III/IV disease with women with tubal factor infertility.

**Conclusion:** Our results suggest that endometriosis does not seem to have adverse effect on outcome of IVF/ ICSI as compared with tubal infertility.

**Key words:** Endometriosis, IVF / ICSI outcome, Tubal factor, Infertility.

## Introduction

Endometriosis is a disease of reproductive-aged women that constitute 20% - 40% of women looking for their infertility diagnosis (1, 2). There are several theories in association with endometriosis, but the theory of retrograde remains dominant (3).

The mechanism by which endometriosis cause infertility has not been completely determined (2), but the factors which have been suggested for infertility in women with endometriosis, include

pelvic adhesions, ovulatory dysfunction, altered folliculogenesis, defective implantation and luteal phase defect (1, 4, 5).

The effect of endometriosis on assisted reproductive outcomes are the issues continuously debated (2, 6, 7). In some studies a reduced response to gonadotropins, and a lower number of oocytes, has been described (5, 8). Several authors reported a significant lower implantation among patients with endometriosis compared with tubal-factor infertility (9, 10). In contrast, in another study, no differences in the number of oocytes, and implantation rates were observed (11).

Matalliotakis *et al* (2007) found that patients with endometriosis had lower peak E<sub>2</sub> levels, higher cancellation rate and lower oocyte reserve than tubal factor groups, but there were no

## Corresponding Author:

Ensieh Shahrokh Tehrani Nejad, Royan Institute, Number 12, East Hafez Avenue, Bani Hashem Street, Resalat Highway, Tehran, Iran. Post Code: 1665659911

**E-mail:** tehraninejad@royaninstitute.org

differences in fertilization, implantation, pregnancy, miscarriage and delivery rates between two groups (7). Some early researchers indicated that pregnancy rates after IVF were significantly higher in women with minimal to mild endometriosis than in those with severe endometriosis (12, 13). Although IVF was initially used for treatment of tubal factor, patients with endometriosis may have anatomic dysfunction of the fallopian tube and ovary, which may need the use of IVF (7).

Considering the presence of controversies in data on the effect of endometriosis on the results of IVF/ICSI treatment, we decided to perform this study. The main objective of this retrospective study was to compare the outcome of IVF/ICSI cycles in women with endometriosis and tubal factor infertility as control and the specific purpose was to explore if the stages of endometriosis influence the results of IVF/ ICSI.

## Materials and methods

Between 2005 and 2006, all the cases of patients with infertility who underwent IVF or ICSI treatment at Royan Institute (Infertility and Reproductive Medicine Research Centre) were assessed and 137 infertile women were identified. The study group consisted of 80 women with endometriosis, while the control population comprised 57 patients with tubal infertility. Endometriosis was scored according to the American Fertility Society classification (1996). Diagnosis of the two groups had previously been confirmed by laparoscopy. Inclusion criteria for the women were age < 37 years, minimum 2 years of infertility, regular menstrual cycle, normal concentrations of prolactin, free thyroxin and thyroid-stimulating hormone (TSH). Patients with polycystic ovaries and women with other known infertility factors besides the endometriosis and tubal factor infertility were excluded. In addition, for the patients, no medical treatment for endometriosis-associated infertility had been performed during at least one year.

All semen samples in both groups were normal (according to the World Health Organization criteria). A standard long protocol was used for COH. In summary, Buserelin acetate 500µg/day (Suprefact<sup>®</sup>, Hoechst, Frankfurt, Germany) was administered subcutaneously on the cycle day 21. After established ovarian suppression (by ultrasound or serum E2 level <50 pg/mL), the dose of GnRh agonist was reduced to 200µg/day, and daily injection of hMG (Menopur; Ferring, the

Netherlands) commenced at doses of 225 IU/day and increased until 450 IU/day depending on the patient's age, body mass index and ovarian response. When there were at least two follicles with a diameter more than 18 mm, Human Chorionic Gonadotrophin (10,000 IU IM, Pregnyl<sup>®</sup>; Darou Pakshsh Pharmaceutical, Tehran, Iran) was administered. Oocyte retrieval by transvaginal guidance was performed 36 hours later. The luteal phase was supported by intramuscular progesterone 100 mg/day (Amp 50 mg; Aburaihan, Tehran, Iran) starting the day before embryo transfer for 2 weeks. In both groups, ICSI was performed for couples who previously had experienced at least one cycle of IVF failure in spite of normal parameters of semen according to WHO standard. The resulting embryo was transferred to the uterus 48-72 hours after oocyte retrieval using ultrasound-guided transvaginal approach. Pregnancy was confirmed by increasing level of concentration of serum βHCG which was assessed 14 days after embryo transfer. The embryos were graded according to their morphology, cleavage stage and fragmentation rate (14). Only the embryos with high quality were transferred.

This study was approved by Royan ethics committee.

## Statistical analysis

Data analysis was performed by means of SPSS version 13.0 software program. Appropriate statistical analysis was performed using  $\chi^2$  and student t-tests. p-values of <0.05 were considered statistically significant.

## Results

In this study, the characteristics and treatment cycle results of patients compared separately between; 1) Women with endometriosis (whole stages) and reference group (tubal infertility) 2) Women with minimal to mild endometriosis (Stage I/II endometriosis) and reference group 3) Women with moderate to severe endometriosis (Stage III/IV endometriosis) and reference group and 4) Women with stage I/II and stage III/IV endometriosis (Tables I and II show the overall results). In comparison of women with endometriosis and women with tubal infertility, no significant differences were seen in the age, body mass index and duration of infertility (Table I).

The women in compared groups were comparable in mean number of ampules of hMG, length of stimulation phase, number of mature

oocytes (MII) and number of embryos transferred. The rate of moderate ovarian hyperstimulation syndrome was also similar in compared groups (Table II).

No significant differences were found between the compared groups with regard to the implantation, pregnancy, miscarriage, ongoing pregnancy and twin birth rates (Table II). Our results showed that the percentage of previous pregnancy was significantly lower in women with endometriosis than women with tubal infertility (6.3% versus 21.1%,  $p=0.01$ ).

According to the results, women with endometriosis also had no history of ectopic pregnancy, while 8 women (14%) in tubal infertility group had previous ectopic pregnancy ( $p=0.001$ ). As indicated in table II, we detected no differences in IVF/ ICSI outcomes when separately compared women with stages I/II endometriosis

and those with stages III/IV disease with patients with tubal infertility. In comparison of stage III/ IV endometriosis and reference group, the mean duration of infertility was significantly lower in women with moderate to severe endometriosis before referral to our assisted reproductive centre. In comparing data in endometriosis patients with stage I/II and stage III/IV disease, no significant differences were observed in results of IVF/ICSI (details are presented in table II).

In following of pregnancies, overall number of preterm labour was two (one case in each group). First trimester vanishing twin was observed in one case in tubal factor group. In two cases of the twin pregnancies in endometriosis-associated group, one of the babies died after birth in the 24<sup>th</sup> days of life due to major malformation and the other died after birth in 28<sup>th</sup> of gestational weeks because of LBW (both women had healthy singletons).

**Table I.** Characteristics of patients.

	Reference group	Endometriosis stages		
		Stage I/II	Stage III/IV	Whole stages
No. of patients	57	40% (32)	60% (48)	80
Age, years (mean $\pm$ SD)	33.7 $\pm$ 4.9	32.5 $\pm$ 5.7	32.3 $\pm$ 4.7	33.0 $\pm$ 5.1
Body mass index (kg/m <sup>2</sup> ) (mean $\pm$ SD)	26.4 $\pm$ 4.6	25.4 $\pm$ 5.45	24.8 $\pm$ 3.77	25.1 $\pm$ 4.5
Duration of infertility (years) (mean $\pm$ SD)	9.6 $\pm$ 6.2	8.5 $\pm$ 5.6	8.1 $\pm$ 5.1*	8.3 $\pm$ 5.2

Reference group = Tubal factor group.

\* =  $p < 0.05$  in comparison with reference group.

The analysis had performed between endometriosis (whole stages) group in comparison with reference group, and also stage I / II and stage III / VI groups together and separately in comparison with reference group.

**Table II.** Results of treatment cycle.

	Reference group	Endometriosis stages		
		Stage I / II	Stage III / VI	Whole stages
No. of ampules of gonadotropin (mean $\pm$ SD)	32.1 $\pm$ 17.2	29.8 $\pm$ 10.8	29.8 $\pm$ 10.8	31.3 $\pm$ 11.9
Duration of stimulation (mean $\pm$ SD)	10.1 $\pm$ 2.1	9.9 $\pm$ 1.7	10.2 $\pm$ 2.4	10.1 $\pm$ 2.1
Moderate OHSS rate (% , n)	12.3% (7)	12.5% (4)	6.3% (3)	%8 (7)
Number of oocytes (MII) (mean $\pm$ SD)	6.5 $\pm$ 4.7	5.8 $\pm$ 3.4	7.0 $\pm$ 6.2	6.6 $\pm$ 5.4
No. of embryos transferred (mean $\pm$ SD)	2.8 $\pm$ 1.3	3.1 $\pm$ 1.1	2.7 $\pm$ 1.5	2.9 $\pm$ 1.4
Implantation rate /embryo transfer (% , n)	11.9%(19/159)	14.3%(14/98)	9.9%(13/131)	11.8%(27/229)
Clinical pregnancy rate /embryo transfer cycle (% , n)	22.6%(12/53)	28.6%(12/42)	25.8% (8/31)	27.4%(20/73)
Miscarriage rate (% , n)	16.6% (2/12)	8.3%(1/12)	12.5% (1/8)	10% (2/20)
Ongoing pregnancy rate (% , n)	18.9% (10/53)	26.2%(11/42)	22.6%(7/31)	24.6%(18/73)
Twin birth /pregnancy (% , n)	33.3%(4/12)	0	37%(3/8)	15%(3/20)

Reference group = Tubal factor group.

The differences between compared groups (endometriosis (Whole stages) group in comparison with reference group, comparison of stage I / II and stage III / VI groups together and separately in comparison with reference group) were Non Significant.

## Discussion

Endometriosis is a known cause of subfertility characterized by the presence of ectopic endometrial glands and stroma and a significant number of child-bearing aged women are affected by endometriosis (2, 15, 16).

Several investigators have found that the duration of hMG used, dosages of gonadotropins, number of oocytes in the endometriosis-associated

group were similar to control group (1, 4, 11). But in the study of Matalliotakis and colleagues (2007), patients with endometriosis required higher dosages of gonadotropins and yielded lower number of oocytes (7). The present study indicated no such differences between the study groups and tubal factor infertility. Our observation demonstrated that implantation and pregnancy rates were similar in both groups. Some studies also corroborate our data (5-7, 17). Basically, it has

been reported that produced cytokines by activated macrophages in peritoneal cavity might have an adverse effect on the follicle, the oocytes, sperm function and gamete interaction or contribute an unsuitable environment for fertilization, and "with IVF/ICSI, the oocyte is not in contact with the peritoneal fluid"(5). Speculating, the presence of endometriosis decreases pregnancy rates for couples who make an effort for conception without ART or with ovulation induction (2).

Apparently, Diaz *et al* (2000) showed that women with advanced endometriosis, receiving oocytes from non-endometriotic ovaries, had an implantation and pregnancy rate similar to that of recipient without endometriosis. This suggests that endometrial receptivity is not impaired in women with endometriosis (18). While in a meta-analysis by Barnhart and associates as well as Surrey *et al* (2002) the negative effect of endometriosis on implantation and pregnancy rates compared with tubal factor infertility was observed (2, 19). In most studies, the abortion rate was not found to be affected in women with endometriosis when compared with the control group (1, 5, 7, 20). Our results also showed no significant difference in rate of pregnancy loss between two groups. The ongoing pregnancy and twin birth rates had no significant differences between women with endometriosis and tubal infertility, similar to some other studies (7, 11).

Analysis of our data indicates that women with endometriosis had no history of ectopic pregnancy, while 14% of women with tubal infertility group had previous ectopic pregnancy. On the basis of studies, history of ectopic pregnancy suggests the possibility of tubal damage and dysfunction (21). Hajenius and associates (2000) reported that tubal patency rate among women with ectopic pregnancy, who desire future fertility, is 80-90% (22), and in another study the OR for tubal pathology after a previous ectopic pregnancy was reported 8.4% (95% CI 6.3 to 12)(23).

According to the results of present study, the percentage of previous pregnancy was significantly lower in women with endometriosis than control group. However there was no significant difference in pregnancy result between two groups of endometriosis and tubal factor in patients with history of pregnancy ( $p=0.28$ ) and patients with no previous pregnancy ( $p=0.82$ ).

We also compared the outcomes of women with stage I/II endometriosis and women with stage III/IV endometriosis with reference group separately. We detected that severity of disease

doesn't have adverse effect on IVF/ICSI outcome. Some authors demonstrated the lower success of IVF with an increase in severity of the disease (1, 2, 12, 24). Conversely, there have been several studies with no differences in IVF pregnancy rates for women with moderate to severe endometriosis than control group (20, 25, 26).

Matalliotakis and colleagues, reported higher gonadotropin requirements, lower oocyte yield in women with advanced stage endometriosis versus women with tubal infertility. However they didn't find any differences in implantation, pregnancy, and delivery rates between the severe endometriosis and tubal factor (7).

In the study of Aboulghar *et al* (2003) no significant differences in mean number of hMG ampules and number of stimulation days observed between patients with severe endometriosis and tubal disease, but the rates of implantation, clinical pregnancy and multiple pregnancy were significantly higher in tubal infertility group (4). We also performed analysis to compare IVF outcome of women with mild and severe endometriosis. Some investigators reported that women with severe endometriosis have a significantly lower implantation and pregnancy rate, versus women with mild endometriosis (2, 12, 13). These results differ from our study which showed no differences in IVF/ICSI outcome between stages of endometriosis. Similarly in the analysis of other studies, no difference observed in pregnancy rate between women with either stage I/II and stage III/IV disease (17, 20, 25- 27).

As indicated, the results of current study showed that the duration of infertility was significantly lower in women with moderate to severe endometriosis than tubal infertility. The etiology is unknown, but an explanation for the present result, might be duo to the clear symptoms of endometriosis than tubal disease, as endometriosis is the most common known cause of pelvic pain. Furthermore dyspareunia, dyschezia, cyclical dysuria and extreme fatigue are all common in women with endometriosis (3, 28).

Thus these patients might refer to doctor sooner for their treatment. Kuivasaari *et al* (2005) reported that the infertility history of women with moderate to severe endometriosis was a few months shorter than women with less severe disease (1). As over the past two decades, there has been a steady decrease in diagnosis of advanced endometriosis at first diagnosis (15).

In conclusion, this study showed that endometriosis does not seem to have adverse effect on ovarian response, quality of oocytes and

pregnancy outcome as compared with tubal infertility.

### Acknowledgement

The authors wish to thank the staff of Royan Institute and Tehran University of Medical Sciences especially Mrs. Nabavi for their cooperation.

### References

1. Kuivasaari P, Hippeläinen M, Anttila M, Heinonen S. Effect of endometriosis on IVF/ICSI outcome: stage III/IV endometriosis worsens cumulative pregnancy and live-born rates. *Hum Reprod* 2005; 20: 3130-3135.
2. Barnhart K, Dunsmoor-Su R, Coutifaris C. Effect of endometriosis on in vitro fertilization. *Fertil Steril* 2002; 77: 1148-1155 Comment in: *Fertil Steril* 2002 Dec; 78: 1350-1351.
3. Denny E, Mann CH. A clinical overview of endometriosis: a misunderstood disease. *Br J Nurs* 2007; 16: 1112-1116.
4. Aboulghar MA, Mansour RT, Serour GI, Al-Inany HG, Aboulghar MM. The outcome of in vitro fertilization in advanced endometriosis with previous surgery: a case-controlled study. *Am J Obstet Gynecol* 2003; 188: 371-375.
5. Bergendal A, Naffah S, Nagy C, Bergqvist A, Sjöblom P, Hillensjö T. Outcome of IVF in patients with endometriosis in comparison with tubal-factor infertility. *J Assist Reprod Genet* 1998; 15: 530-534.
6. Omland AK, Fedorcsák P, Storeng R, Dale PO, Abyholm T, Tanbo T. Natural cycle IVF in unexplained, endometriosis-associated and tubal factor infertility. *Hum Reprod* 2001; 16: 2587-2592. Comment in: *Hum Reprod* 2002; 17: 1926-1927.
7. Matalliotakis IM, Cakmak H, Mahutte N, Fragouli Y, Arici A, Sakkas D. Women with advanced-stage endometriosis and previous surgery respond less well to gonadotropin stimulation, but have similar IVF implantation and delivery rates compared with women with tubal factor infertility. *Fertil Steril* 2007; 88: 1568-1572.
8. Mahutte NG, Arici A. Endometriosis and assisted reproductive technologies: are outcomes affected? *Curr Opin Obstet Gynecol* 2001; 13: 275-279.
9. Marcoux S, Maheux R, Bérubé S. Laparoscopic surgery in infertile women with minimal or mild endometriosis. Canadian Collaborative Group on Endometriosis. *N Engl J Med* 1997; 337: 217-222.
10. Garcia-Velasco JA, Nikas G, Remohí J, Pellicer A, Simón C. Endometrial receptivity in terms of pinopode expression is not impaired in women with endometriosis in artificially prepared cycles. *Fertil Steril* 2001; 75: 1231-1233.
11. Omland AK, Abyholm T, Fedorcsák P, Ertzeid G, Oldereid NB, Bjercke S, et al. Pregnancy outcome after IVF and ICSI in unexplained, endometriosis-associated and tubal factor infertility. *Hum Reprod* 2005; 20: 722-727.
12. Chillik CF, Acosta AA, Garcia JE, Perera J, Van Uem JFH, Rosenwaks Z, et al. The role of in vitro fertilization in infertile patients with endometriosis. *Fertil Steril* 1985; 44: 56-61.
13. Yovich JL, Matson PL. The influence of infertility etiology on the outcome of IVF-ET and GIFT treatments. *Int J Fertil* 1990; 35: 26-33.
14. Baczkowski T, Kurzawa R, Głabowski W. Methods of embryo scoring in in vitro fertilization. *Reprod Biol* 2004; 4: 5-22.
15. Dmowski WP, Lesniewicz R, Rana N, Pepping P, Noursalehi M. Changing trends in the diagnosis of endometriosis: a comparative study of women with pelvic endometriosis presenting with chronic pelvic pain or infertility. *Fertil Steril* 1997; 67: 238-243.
16. Chandra Sekhar, Netaji Bendi, Baludu Simha G, Roya Rozati. Evaluation of the Phthalate Esters in South Indian Women with Endometriosis. *IJFS* 2007;1: 165-170.
17. Pal L, Shifren JL, Isaacson KB, Chang Y, Leykin L, Toth TL. Impact of varying stages of endometriosis on the outcome of in vitro fertilization-embryo transfer. *J Assist Reprod Genet* 1998; 15: 27-31.
18. Díaz I, Navarro J, Blasco L, Simón C, Pellicer A, Remohí J. Impact of stage III-IV endometriosis on recipients of sibling oocytes: matched case-control study. *Fertil Steril* 2000; 74: 31-34.
19. Surrey ES, Silverberg KM, Surrey MW, Schoolcraft WB. Effect of prolonged gonadotropin-releasing hormone agonist therapy on the outcome of in vitro fertilization-embryo transfer in patients with endometriosis. *Fertil Steril* 2002; 78: 699-704.
20. Geber S, Paraschos T, Atkinson G, Margara R, Winston RM. Results of IVF in patients with endometriosis: the severity of the disease does not affect outcome, or the incidence of miscarriage. *Hum Reprod* 1995; 10: 1507-1511.
21. Speroff L, Fritz MA. Clinical Gynecologic Endocrinology and Infertility. 7th ed. Philadelphia: Lippincott Williams and Wilkins; 2005: 1046
22. Hajenius PJ, Mol BW, Bossuyt PM, Ankum WM, Van Der Veen F. Interventions for tubal ectopic pregnancy. *Cochrane Database Syst Rev* 2000; (2): CD000324 Update in: *Cochrane Database Syst Rev*. 2007; (1): CD000324.
23. Verhoeve HR, Steures P, Flierman PA, van der Veen F, Mol BW. History of induced abortion and the risk of tubal pathology. *Reprod Biomed Online* 2008; 16: 304-307.
24. Azem F, Lessing JB, Geva E, Shahar A, Lerner-Geva L, Yovel I, et al. Patients with stages III and IV endometriosis have a poorer outcome on in vitro fertilization-embryo transfer than patients with tubal infertility. *Fertil Steril* 1999; 72: 1107-1109.
25. Dmowski WP, Rana N, Michalowska J, Friberg J, Papierniak C, el-Roeiy A. The effect of endometriosis, its stage and activity and of autoantibodies on in vitro fertilization and embryo transfer success rates. *Fertil Steril* 1995; 63: 555-562.
26. Olivennes F, Feldberg D, Liu HC, Cohen J, Moy F, Rosenwaks Z. Endometriosis: a stage by stage analysis—the role of in vitro fertilization. *Fertil Steril* 1995; 63: 392-398.
27. Arici A, Oral E, Bukulmez O, Duleba A, Olive DL, Jones EE. The effect of endometriosis on implantation: results from the Yale University in vitro fertilization and embryo transfer program. *Fertil Steril* 1996; 65:603-607.
28. Salehpour S, Khalili L, Zhaam H, Azar Gashb Y, Hakimifard M. Evaluation of Diagnostic Visual Findings at Laparoscopy in Endometriosis. *IJFS* 2007; 1: 123-126.

